Search results for "Axel"

showing 10 items of 257 documents

<p>Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life</p>

2019

Objective Metastatic breast cancer (MBC) is an incurable disease; the treatment of this disease prolongs survival, improving the quality of life (QoL) with a balance between efficacy and toxicity of the treatment. In recent years, treatment with nab-paclitaxel has improved the already known antitumor activity of conventional paclitaxel, in terms of increased efficacy and better tolerability. The aim of this study was to evaluate nab-paclitaxel in Italian patients with MBC. Methods We conducted a retrospective analysis of 90 patients with histologically confirmed diagnosis of MBC. To evaluate the efficacy of nab-paclitaxel, overall survival (OS), progression-free survival (PFS), and overall …

0301 basic medicineOncologyCA15-3medicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentDiseasemedicine.diseaseMetastatic breast cancer03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineOncologyQuality of lifePaclitaxelchemistryTolerability030220 oncology & carcinogenesisInternal medicineToxicitymedicinePharmacology (medical)businessOncoTargets and Therapy
researchProduct

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

2019

A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has ‘aggressive disease’, as reflected in short time to progression or lack of disease control with initial platinum-based chemotherapy. Recently, clinical correlates of aggressive disease behavior during first-line therapy have been shown to predict greater benefit from addition of nintedanib to second-line docetaxel in adenocarcinoma NSCLC. Positive predictive effects of aggressive disease have since been reported with other anti-angiogenic agents (ramucirumab and bevacizumab), while such features may negatively impact on outcomes with nivolumab in nonsquamous NSCLC with low PD-L1 expression…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyIndolesLung NeoplasmsTime FactorsBevacizumabmedicine.medical_treatmentDocetaxelAntibodies Monoclonal HumanizedDisease-Free SurvivalRamucirumab03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerLungChemotherapybusiness.industryPatient SelectionAntibodies MonoclonalGeneral Medicinemedicine.diseaserespiratory tract diseasesBevacizumab030104 developmental biologyOncologychemistryDocetaxel030220 oncology & carcinogenesisDisease ProgressionAdenocarcinomaNintedanibNivolumabbusinessmedicine.drugFuture oncology (London, England)
researchProduct

Trifluridine/tipiracil : an emerging strategy for the management of gastrointestinal cancers

2018

Fluoropyrimidines are currently the backbone of treatment for gastrointestinal (GI) cancers but development of resistance to these agents remains a major problem. Trifluridine/tipiracil is an oral chemotherapeutic agent recently approved for third-line treatment of chemorefractory metastatic colorectal cancer. This article reviews the clinical value of trifluridine/tipiracil as a monotherapy, including recent trials in GI cancers, and the potential benefit of combining it with other agents in patients with GI cancers, including the preclinical rationale for combination therapy and recently completed and ongoing clinical trials. Data gathered so far suggest that trifluridine/tipiracil has t…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyIndolesPyrrolidinesOrganoplatinum CompoundsCombination therapyColorectal cancerTrifluridineDocetaxelIrinotecanTrifluridine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansGastrointestinal cancerContinuum of careUracilGastrointestinal NeoplasmsTipiracilClinical Trials as Topicbusiness.industryGeneral Medicinemedicine.diseaseBevacizumabOxaliplatinClinical trialDrug Combinations030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisColonic NeoplasmsQuality of LifeClinical valueCamptothecinTaxoidsFluorouracilImmunotherapyHuman medicinebusinessThyminemedicine.drugFuture oncology
researchProduct

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

2017

Purpose To analyze the impact of postmastectomy radiation therapy (PMRT) for patients with T1-T2 tumors and 1 to 3 positive lymph nodes enrolled on the Breast International Group (BIG) 02-98 trial. Methods and Materials The BIG 02-98 trial randomized patients to receive adjuvant anthracycline with or without taxane chemotherapy. Delivery of PMRT was nonrandomized and performed according to institutional preferences. The present analysis was performed on participants with T1-T2 breast cancer and 1 to 3 positive lymph nodes who had undergone mastectomy and axillary nodal dissection. The primary objective of the present study was to examine the effect of PMRT on risk of locoregional recurrence…

0301 basic medicineOncologyCancer Researchmedicine.medical_treatmentDocetaxelMastectomy Segmentallaw.invention0302 clinical medicineRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsAnthracyclinesMastectomyRadiationHazard ratioCarcinoma Ductal BreastMiddle Agedmedicine.anatomical_structureEditorialOncologyDocetaxelChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleMastectomymedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsBreast Neoplasms03 medical and health sciencesYoung AdultBreast cancerInternal medicinemedicineConfidence IntervalsHumansRadiology Nuclear Medicine and imagingCyclophosphamideAgedNeoplasm StagingPostoperative Carebusiness.industryCancermedicine.diseaseClinical trialAxilla030104 developmental biologyDoxorubicinAxillaLymph Node ExcisionLymph NodesbusinessInternational journal of radiation oncology, biology, physics
researchProduct

Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.

2019

BackgroundIn this study based on the BRENDA data, we investigated the impact of endocrine ± chemotherapy for luminal A, nodal positive breast cancer on recurrence free (RFS) and overall survival (OS). In addition, we analysed if tumor size of luminal A breast cancer influences survival in patients with the same number of positive lymph nodes.MethodsIn this retrospective multi-centre cohort study data of 1376 nodal-positive patients with primary diagnosis of luminal A breast cancer during 2001-2008 were analysed. The results were stratified by therapy and adjusted by age, tumor size and number of affected lymph nodes.ResultsIn our study population, patients had a good to excellent prognosis …

0301 basic medicineOncologyDose-dense chemotherapyAdjuvant Chemotherapymedicine.medical_treatmentCancer Treatment0302 clinical medicineBreast TumorsMedicine and Health SciencesEndocrine TumorsMultidisciplinaryPharmaceuticsQREndocrine TherapyMiddle AgedPrognosisSurvival RateOncologyDocetaxelChemotherapy AdjuvantLymphatic Metastasis030220 oncology & carcinogenesisMedicineFemaleLymphAnatomyResearch Articlemedicine.drugClinical Oncologymedicine.medical_specialtyScienceBreast NeoplasmsDisease-Free SurvivalLymphatic SystemCancer Chemotherapy03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancermedicineHumansChemotherapyEndocrine systemSurvival rateAgedRetrospective StudiesChemotherapybusiness.industryBiology and Life SciencesCancers and NeoplasmsRetrospective cohort studymedicine.disease030104 developmental biologyLymph NodesClinical MedicinebusinessPLoS ONE
researchProduct

The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.

2017

<b><i>Background/Aim:</i></b> Prostate cancer frequently causes bone metastases and skeletal events that impair quality of life (QoL) and survival. The alpha emitter radium-223 is a new drug that improves treatment in men with castration-resistant prostate cancer (CRPC) and bone metastases. Our aim was to evaluate the effectiveness of radium-223. <b><i>Subjects and Methods:</i></b> In this retrospective study we enrolled 48 subjects. Pain reduction, alkaline phosphatase (ALP), time to first symptomatic skeletal event, and QoL were the variables we evaluated. <b><i>Results:</i></b> Radium-223 was well tolerated, with a m…

0301 basic medicineOncologyDrugRadium-223MaleCancer Researchmedicine.medical_specialtymedia_common.quotation_subjectAntineoplastic AgentsBone NeoplasmsDocetaxel03 medical and health sciencesProstate cancer0302 clinical medicineQuality of lifeInternal medicinemedicineHumansmedia_commonAgedRetrospective StudiesAged 80 and overRadioisotopesbusiness.industryBone metastasisRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseProstatic Neoplasms Castration-Resistant030104 developmental biologyOncologyDocetaxelItaly030220 oncology & carcinogenesisQuality of LifeAlkaline phosphatasePrednisoneTaxoidsRadium-223 Bone metastasis Prostate cancer Radiopharmaceuticals Metastatic castration-resistant prostate cancer Quality of Lifebusinessmedicine.drugRadiumOncology
researchProduct

Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?

2016

Tumor angiogenesis is one of the main pathways targeted to treat cancer. Bevacizumab added survival benefit when combined with platinum-based chemotherapy in NSCLC. Recently, Phase III trials showed survival benefit when anti-angiogenic drugs are added to docetaxel as second-line treatment for NSCLC. These anti-angiogenic agents include nintedanib and ramucirumab, a tyrosine-kinase inhibitor and a monoclonal antibody, respectively, which target receptors involved in angiogenesis. These studies have some similarities and differences. We propose a new algorithm for treatment sequences in performance status 0-1 patients with non-oncogene-addicted NSCLC type adenocarcinoma. Indeed clearer scien…

0301 basic medicineOncologyIndolesLung NeoplasmsAngiogenesisInvestigationalangiogenesis; docetaxel; nintedanib; NSCLC; ramucirumab; Angiogenesis Inhibitors; Antibodies; Monoclonal; Carcinoma; Non-Small-Cell Lung; Chemotherapy; Adjuvant; Humans; Indoles; Lung Neoplasms; Neovascularization; Pathologic; Practice Guidelines as Topic; Protein Kinase Inhibitors; Taxoids; Therapies; Investigational; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Clinical BiochemistryClinical BiochemistryAngiogenesis InhibitorsNSCLCangiogenesischemistry.chemical_compound0302 clinical medicineCarcinoma Non-Small-Cell LungMonoclonalDrug DiscoverynintedanibdocetaxelNon-Small-Cell LungAdjuvantNeovascularization PathologicTherapies InvestigationalAntibodies MonoclonalDocetaxelChemotherapy Adjuvant030220 oncology & carcinogenesisPractice Guidelines as TopicAdenocarcinomaTaxoidsNintedanibAngiogenesis InhibitorHumanmedicine.drugmedicine.medical_specialtyBevacizumabramucirumabProtein Kinase InhibitorAntibodies Monoclonal HumanizedAntibodiesRamucirumab03 medical and health sciencesTaxoidInternal medicinemedicineChemotherapyHumansProtein Kinase InhibitorsNeovascularizationPathologicPharmacologyPerformance statusbusiness.industryDrug Discovery3003 Pharmaceutical ScienceCarcinomaangiogenesiCancermedicine.diseaseLung Neoplasm030104 developmental biologychemistryIndoleTherapiesangiogenesis; docetaxel; nintedanib; NSCLC; ramucirumab; Angiogenesis Inhibitors; Antibodies Monoclonal; Carcinoma Non-Small-Cell Lung; Chemotherapy Adjuvant; Humans; Indoles; Lung Neoplasms; Neovascularization Pathologic; Practice Guidelines as Topic; Protein Kinase Inhibitors; Taxoids; Therapies Investigational; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Clinical BiochemistrybusinessExpert Opinion on Biological Therapy
researchProduct

Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer.

2017

<b><i>Background/Aim:</i></b> A clinical trial demonstrated that treatment with oral multikinase regorafenib improved overall survival (OS), progression-free survival (PFS), and disease control [García-Alfonso et al.: J Clin Transl Oncol 2016;18:1072-1081; Bertocchi et al.: J Chemother 2017;29:102-105]. In this study, we aimed to evaluate its effectiveness in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy with docetaxel plus prednisone. <b><i>Materials and Methods:</i></b> 60 patients were enrolled. OS has been assessed as the primary endpoint while PFS, quality o…

0301 basic medicineOncologyMaleCancer ResearchColorectal cancerPyridinesmedicine.medical_treatmentDocetaxelKaplan-Meier Estimatechemistry.chemical_compound0302 clinical medicineQuality of lifeAntineoplastic Combined Chemotherapy ProtocolsMedicineRegorafenibAged 80 and overMetastatic colorectal cancerGeneral MedicineMiddle AgedProstatic Neoplasms Castration-ResistantTreatment OutcomeOncology030220 oncology & carcinogenesisAdenocarcinomaFemaleTaxoidsColorectal NeoplasmsAdultmedicine.medical_specialtyAntineoplastic AgentsAdenocarcinomaDisease-Free Survival03 medical and health sciencesRegorafenibInternal medicineOverall survivalChemotherapyHumansAgedRetrospective StudiesChemotherapybusiness.industryPhenylurea Compoundsmedicine.diseaseClinical trial030104 developmental biologychemistryQuality of LifePrednisonebusinessOncology
researchProduct

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

2018

Abstract Background There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of nintedanib, a triple angiokinase inhibitor, plus cisplatin/gemcitabine as first-line treatment for advanced sqNSCLC patients, were evaluated. Materials and methods A phase I, dose-escalation study administering drugs in a 21-day cycle: cisplatin (75 mg/m2, Day 1), gemcitabine (1250 mg/m2, Days 1 and 8) and nintedanib (Days 2–7, 9–21) were given for 4–6 cycles, followed by monotherapy until disease progression or adverse events (AEs). Two nintedanib doses were tested, 150 mg twice daily (bid) and 200 mg bid, to determine…

0301 basic medicineOncologyMaleCancer ResearchPHARMACOKINETICSIndolesLung NeoplasmsPACLITAXELDeoxycytidineANGIOGENESISSquamouschemistry.chemical_compound0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsBIBF 1120Aged 80 and overMiddle AgedPrognosisTreatment OutcomeOncologyPaclitaxelLABEL DOSE-ESCALATION030220 oncology & carcinogenesisNintedanibFemaleCLINICAL-PRACTICE GUIDELINESmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyBevacizumabMaximum Tolerated DoseNintedanibBEVACIZUMABCONTROLLED-TRIALDisease-Free Survival03 medical and health sciencesPharmacokineticsInternal medicinemedicineHumansAdverse effectAgedNeoplasm StagingTRIPLE ANGIOKINASE INHIBITORCisplatinCARBOPLATINbusiness.industryGemcitabineCarboplatinGemcitabine030104 developmental biologychemistryCisplatinbusinessLung Cancer
researchProduct

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and pac…

2018

Summary Purpose To investigate the safety and clinical activity of comprehensive human epidermal growth factor receptor (HER) family receptor inhibition using lumretuzumab (anti-HER3) and pertuzumab (anti-HER2) in combination with paclitaxel in patients with metastatic breast cancer (MBC). Methods This phase Ib study enrolled 35 MBC patients (first line or higher) with HER3-positive and HER2-low (immunohistochemistry 1+ to 2+ and in-situ hybridization negative) tumors. Patients received lumretuzumab (1000 mg in Cohort 1; 500 mg in Cohorts 2 and 3) plus pertuzumab (840 mg loading dose [LD] followed by 420 mg in Cohorts 1 and 2; 420 mg without LD in Cohort 3) every 3 weeks, plus paclitaxel (8…

0301 basic medicineOncologyMaleReceptor ErbB-3Receptor ErbB-2Medizinchemistry.chemical_compound0302 clinical medicineErbB3Phase I StudiesAntineoplastic Combined Chemotherapy ProtocolsMedicinePharmacology (medical)skin and connective tissue diseasesMiddle AgedMetastatic breast cancerMetastatic breast cancerDiarrheaOncologyPaclitaxel030220 oncology & carcinogenesisMarcadors bioquímicsCohortFemalePertuzumabmedicine.symptommedicine.drugAdultDiarrheamedicine.medical_specialtyLoperamidePaclitaxelMama -- Càncer -- TractamentAntineoplastic AgentsBreast NeoplasmsHypokalemiaAntibodies Monoclonal HumanizedLoading dosePolymorphism Single Nucleotide03 medical and health sciencesPhase IHuman epidermal growth factor receptor 3 (HER3)Internal medicineHumansAgedPharmacologyPertuzumabbusiness.industryBiomarkerLumretuzumabmedicine.disease030104 developmental biologychemistryHuman epidermal growth factor receptor 2 (HER2)businessHeregulin (HRG)
researchProduct